U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market (2025 - 2030) Size, Share & Trends Analysis Report By Molecule (Small Molecule, Large Molecule), By Application (Oncology, Immunology, Antidiabetic, Neurology, Cardiovascular), And Segment Forecasts
- Report Summary
- Table of Contents
- Segmentation
- Methodology
- Download FREE Sample
-
Download Sample Report
Table of Contents
Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Molecule
1.2.2. Application
1.3. Regional Scope
1.4. Estimates And Forecast Timeline
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising frequency of patent expirations for blockbuster drugs
3.2.1.2. Streamlined regulatory pathway and low cost of generics
3.2.1.3. Increasing penetration of CDMOs in the generic injectables space
3.2.2. Market Restraint Analysis
3.2.2.1. Presence of substitute therapies
3.2.2.2. Compliance issues while outsourcing
3.3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market: Molecule Estimates & Trend Analysis
4.1. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, By Molecule: Segment Dashboard
4.2. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, By Molecule: Movement Analysis
4.3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Molecule, 2018 - 2030
4.3.1. Small Molecule
4.3.1.1. Small Molecule Market, 2018 to 2030 (USD Million)
4.3.2. Large Molecule
4.3.2.1. Large Molecule Market, 2018 to 2030 (USD Million)
Chapter 5. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market: Application Estimates & Trend Analysis
5.1. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, By Application: Segment Dashboard
5.2. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, By Application: Movement Analysis
5.3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Application, 2018 - 2030
5.3.1. Oncology
5.3.1.1. Oncology Market, 2018 to 2030 (USD Million)
5.3.2. Immunology
5.3.2.1. Immunology Market, 2018 to 2030 (USD Million)
5.3.3. Antidiabetic
5.3.3.1. Antidiabetic Market, 2018 to 2030 (USD Million)
5.3.4. Neurology
5.3.4.1. Neurology Market, 2018 to 2030 (USD Million)
5.3.5. Cardiovascular
5.3.5.1. Cardiovascular Market, 2018 to 2030 (USD Million)
5.3.6. Respiratory
5.3.6.1. Respiratory Market, 2018 to 2030 (USD Million)
5.3.7. Others
5.3.7.1. Others Market, 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Market Participant Categorization
6.1.1. Innovators
6.1.2. Market Leaders
6.1.3. Emerging Players
6.1.4. Company Market Share Analysis, 2024
6.2. Company Profiles
6.2.1. Charles River Laboratories International, Inc.
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Service Benchmarking
6.2.1.4. Strategic Initiatives
6.2.2. Hikma Pharmaceuticals PLC
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Service Benchmarking
6.2.2.4. Strategic Initiatives
6.2.3. Pfizer Inc.
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Service Benchmarking
6.2.3.4. Strategic Initiatives
6.2.4. Fresenius Kabi
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Service Benchmarking
6.2.4.4. Strategic Initiatives
6.2.5. Sandoz AG
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Service Benchmarking
6.2.5.4. Strategic Initiatives
6.2.6. Jubilant Pharma Limited
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Service Benchmarking
6.2.6.4. Strategic Initiatives
6.2.7. Baxter
6.2.7.1. Company Overview
6.2.7.2. Financial Performance
6.2.7.3. Service Benchmarking
6.2.7.4. Strategic Initiatives
6.2.8. PCI Pharma Services.
6.2.8.1. Company Overview
6.2.8.2. Financial Performance
6.2.8.3. Service Benchmarking
6.2.8.4. Strategic Initiatives
6.2.9. Gland Pharma Limited (USA)
6.2.9.1. Company Overview
6.2.9.2. Financial Performance
6.2.9.3. Service Benchmarking
6.2.9.4. Strategic Initiatives
6.2.10. Dr.Reddy’s Laboratories Ltd.
6.2.10.1. Company Overview
6.2.10.2. Financial Performance
6.2.10.3. Service Benchmarking
6.2.10.4. Strategic Initiatives
6.2.11. Grand River Aseptic Manufacturing
6.2.11.1. Company Overview
6.2.11.2. Financial Performance
6.2.11.3. Service Benchmarking
6.2.11.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 U.S. Generic Injectables Pharmaceutical Contract Manufacturing market, by Molecule, 2018 - 2030 (USD Million)
Table 4 U.S. Generic Injectables Pharmaceutical Contract Manufacturing market, by Application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market revenue, 2018 - 2030 (USD Million)
Fig. 10 U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market snapshot
Fig. 11 U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market driver impact
Fig. 12 U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market restraint impact
Fig. 13 U.S. Generic Injectables Pharmaceutical Contract Manufacturing molecule key takeaways (USD Million)
Fig. 14 U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market: Molecule movement analysis
Fig. 15 Small molecule market, 2018 - 2030 (USD Million)
Fig. 16 Large molecule market, 2018 - 2030 (USD Million)
Fig. 17 U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Application key takeaways (USD Million)
Fig. 18 U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market: Application movement analysis
Fig. 19 Oncology market, 2018 - 2030 (USD Million)
Fig. 20 Immunology market, 2018 - 2030 (USD Million)
Fig. 21 Antidiabetic market, 2018 - 2030 (USD Million)
Fig. 22 Neurology market, 2018 - 2030 (USD Million)
Fig. 23 Cardiovascular market, 2018 - 2030 (USD Million)
Fig. 24 Respiratory market, 2018 - 2030 (USD Million)
Fig. 25 Others market, 2018 - 2030 (USD Million)
Fig. 26 Market participant categorization
Get Free Sample Report
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
Trusted market insights - try a free sample
See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.
